Lisinopril Dosing and Management for Hypertension

Initial Dosing and Titration

The American College of Cardiology recommends allowing at least 4 weeks between dose adjustments to observe the full blood pressure response, unless more urgent BP lowering is required 1

Most patients with hypertension require at least two drugs to achieve blood pressure goals, according to the British Medical Journal 2, 3
For stage 2 hypertension (BP ≥160/100 mmHg), initiate two antihypertensive agents simultaneously rather than sequential monotherapy, as recommended by Diabetes Care 4
ACE inhibitors like lisinopril are first-line therapy for hypertensive patients with diabetes and albuminuria (urinary albumin-to-creatinine ratio ≥30 mg/g), according to Diabetes Care 4
Target blood pressure <130/80 mmHg in patients with diabetes or chronic kidney disease, as recommended by the British Medical Journal 2, 3

Monitor serum creatinine, estimated GFR, and potassium levels at least annually, more frequently in patients on diuretics or with renal impairment, as recommended by Diabetes Care 4
An increase in creatinine up to 50% above baseline or to 3 mg/dL (266 μmol/L), whichever is greater, is acceptable, according to the European Journal of Heart Failure 5
Potassium levels up to 5.5-6.0 mmol/L may be acceptable with careful monitoring, as stated in the European Journal of Heart Failure 5

Do not combine lisinopril with ARBs or direct renin inhibitors, as this increases adverse effects without additional benefit, according to Diabetes Care 4

The ALLHAT trial demonstrated that lisinopril 10-40 mg daily was equally effective as chlorthalidone and amlodipine for the primary outcome of fatal CHD and nonfatal MI, as reported in the Journal of the American Society of Nephrology 6
Lisinopril is an appropriate first-line agent, particularly in patients with specific indications such as diabetes, chronic kidney disease, or heart failure, according to the British Medical Journal 1, 2

The American College of Cardiology recommends initiation with two antihypertensive agents of different classes for patients with stage 2 hypertension (BP ≥160/100 mm Hg) 7, 8
The American Heart Association suggests combination therapy (preferably with a single pill combination) as initial treatment for patients with stage 2 hypertension 8, 9
For elderly patients with hypertension, low-dose thiazides are generally preferred first-line, and when ACE inhibitors like lisinopril are used, careful monitoring for hypotension is recommended, especially if combined with diuretics 10

The American College of Cardiology recommends follow-up evaluation of adherence and response to treatment at monthly intervals until blood pressure control is achieved, and to allow at least 4 weeks to observe the full response before making dose adjustments, unless urgent BP lowering is required 10, 8, 11
Patients taking lisinopril should be monitored for common side effects including cough, dizziness, headache, and hyperkalemia, and particular attention should be paid to renal function and potassium levels, especially in patients with chronic kidney disease or those taking potassium supplements or potassium-sparing diuretics 7

The American College of Cardiology recommends avoiding the use of lisinopril in pregnancy due to the risk of fetal harm, and not using it in combination with ARBs or direct renin inhibitors due to increased risk of adverse effects without additional benefit 7

The American Academy of Pediatrics recommends a starting dose of 0.07 mg/kg once daily for pediatric patients ≥6 years, with a maximum initial dose of 5 mg 12
Lisinopril is absolutely contraindicated in pregnancy due to fetal toxicity 12

The British Medical Journal suggests titrating upward according to blood pressure response, increasing the dose incrementally, with most patients requiring at least two antihypertensive drugs to achieve blood pressure goals 13, 14
Submaximal doses of two drugs produce larger BP responses with fewer side effects than maximal doses of a single drug 13, 14

The British Medical Journal recommends using caution in patients with peripheral vascular disease due to association with renovascular disease 13